OBJECTIVE: To investigate the impact of statins on perihematomal edema following spontaneous supratentorial intracerebral hemorrhage (ICH). BACKGROUND: Hematoma expansion and evolution of perihematomal edema are most commonly responsible for neurological deterioration following ICH. A possible role of statins in reducing perihematomal edema has been suggested based on studies in animal models. METHODS: Records of consecutive ICH patients admitted to The Johns Hopkins Hospital from 1999 to 2006 were reviewed. Patients with ICH related to trauma or underlying lesions (e.g., brain tumors, aneurysms, and arterio-venous malformations) and of infratentorial location were excluded. Absolute and relative perihematomal edema were assessed on initial head CT. Using regression analysis, the impact of prior statin use on absolute and relative edema at presentation was assessed correcting for other factors possibly impacting perihematomal edema, such as age, coagulopathy, aspirin use, admission mean arterial pressure (MAP), and blood glucose. RESULTS: A total of 125 consecutive ICH patients were studied. Patients with prior statin exposure had a mean edema volume of 13.2 +/- 9.2 cc compared to 22.3 +/- 18.3 cc in patients who were not using statins at the time of ICH. Following multiple linear regression analysis, we have identified a statistically significant association between prior statin use with reduced early absolute perihematomal edema (P = 0.035). Mean relative perihematomal edema was significantly lower in patients on statins at presentation (0.44) as opposed to 0.81 in patients with no prior statin use. This difference remained statistically significant (P = 0.021) after correcting for other variables. CONCLUSIONS: We report the association between statin use prior to ICH and decreased absolute and relative perihematomal edema. A prospective study analyzing the role of statins in perihematomal edema reduction and the resultant effect on mortality and functional outcomes following ICH is warranted.
OBJECTIVE: To investigate the impact of statins on perihematomal edema following spontaneous supratentorial intracerebral hemorrhage (ICH). BACKGROUND:Hematoma expansion and evolution of perihematomal edema are most commonly responsible for neurological deterioration following ICH. A possible role of statins in reducing perihematomal edema has been suggested based on studies in animal models. METHODS: Records of consecutive ICHpatients admitted to The Johns Hopkins Hospital from 1999 to 2006 were reviewed. Patients with ICH related to trauma or underlying lesions (e.g., brain tumors, aneurysms, and arterio-venous malformations) and of infratentorial location were excluded. Absolute and relative perihematomal edema were assessed on initial head CT. Using regression analysis, the impact of prior statin use on absolute and relative edema at presentation was assessed correcting for other factors possibly impacting perihematomal edema, such as age, coagulopathy, aspirin use, admission mean arterial pressure (MAP), and blood glucose. RESULTS: A total of 125 consecutive ICHpatients were studied. Patients with prior statin exposure had a mean edema volume of 13.2 +/- 9.2 cc compared to 22.3 +/- 18.3 cc in patients who were not using statins at the time of ICH. Following multiple linear regression analysis, we have identified a statistically significant association between prior statin use with reduced early absolute perihematomal edema (P = 0.035). Mean relative perihematomal edema was significantly lower in patients on statins at presentation (0.44) as opposed to 0.81 in patients with no prior statin use. This difference remained statistically significant (P = 0.021) after correcting for other variables. CONCLUSIONS: We report the association between statin use prior to ICH and decreased absolute and relative perihematomal edema. A prospective study analyzing the role of statins in perihematomal edema reduction and the resultant effect on mortality and functional outcomes following ICH is warranted.
Authors: Matthew J McGirt; John R Lynch; Augusto Parra; Huaxin Sheng; Robert D Pearlstein; Daniel T Laskowitz; Dale A Pelligrino; David S Warner Journal: Stroke Date: 2002-12 Impact factor: 7.914
Authors: E Fainardi; M Borrelli; A Saletti; R Schivalocchi; M Russo; C Azzini; M Cavallo; S Ceruti; R Tamarozzi; A Chieregato Journal: Acta Neurochir Suppl Date: 2006
Authors: Tavarekere N Nagaraja; Robert A Knight; Richard L Croxen; Kirthi P Konda; Joseph D Fenstermacher Journal: Neurol Res Date: 2006-12 Impact factor: 2.448
Authors: Ken S Butcher; Tracey Baird; Lachlan MacGregor; Patricia Desmond; Brian Tress; Stephen Davis Journal: Stroke Date: 2004-06-03 Impact factor: 7.914
Authors: Laura C Gioia; Mahesh Kate; Rebecca McCourt; Bronwen Gould; Shelagh B Coutts; Dariush Dowlatshahi; Negar Asdaghi; Thomas Jeerakathil; Michael D Hill; Andrew M Demchuk; Brian Buck; Derek Emery; Ashfaq Shuaib; Kenneth Butcher Journal: J Cereb Blood Flow Metab Date: 2015-03-11 Impact factor: 6.200
Authors: Sebastian Urday; W Taylor Kimberly; Lauren A Beslow; Alexander O Vortmeyer; Magdy H Selim; Jonathan Rosand; J Marc Simard; Kevin N Sheth Journal: Nat Rev Neurol Date: 2015-01-27 Impact factor: 42.937
Authors: Audrey Leasure; W Taylor Kimberly; Lauren H Sansing; Kristopher T Kahle; Golo Kronenberg; Hagen Kunte; J Marc Simard; Kevin N Sheth Journal: Curr Treat Options Neurol Date: 2016-02 Impact factor: 3.598
Authors: Dongmei Yang; Robert A Knight; Yuxia Han; Kishor Karki; Jianfeng Zhang; Michael Chopp; Donald M Seyfried Journal: J Behav Brain Sci Date: 2012-12-10